COMMUNIQUÉS West-GlobeNewswire

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼
09/03/2026
Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval from every-two-weeks to every-four-weeks for those stable with an enzyme [...]
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
09/03/2026
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today [...]
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
09/03/2026
NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
09/03/2026
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry [...]
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
09/03/2026
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
09/03/2026
Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucel Smital Shah appointed Chief Financial and Business Officer SOUTH [...]
Route 92 Medical Enrolls First Patient in SUMMIT RISE Study
09/03/2026
SUMMIT RISE is expected to enroll up to 500 patients to evaluate the performance of Route 92 Medical’s neurovascular intervention device portfolio WEST JORDAN, Utah, March 09, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, [...]
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
09/03/2026
97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months 100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating [...]
Hyperion DeFi Announces Private Lending Pool Built by HyperLend
09/03/2026
Unlocks Cost-Optimized On-Chain Credit Access, Additional Ecosystem Rewards, and Expanded Revenue Opportunities in Institutional Credit LAGUNA HILLS, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. ( [...]
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
09/03/2026
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to [...]
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders
09/03/2026
-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with [...]
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
09/03/2026
Dr. Robert Lenz brings over 20 years of experience in neuroscience drug development NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late- [...]
BeautyHealth Expands Skin Health Ecosystem with Growing Adoption of SkinStylus Nano-Channeling, a Popular Pairing with Hydrafacial Treatments
09/03/2026
The Hydrafacial Treatment and SkinStylus Nano-Channeling Protocol Addresses Rising Consumer Demand for Combination Treatments That Can Improve Performance and Enhance Results LONG BEACH, Calif., March 09, 2026 (GLOBE [...]
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company [...]
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
09/03/2026
BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
09/03/2026
CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No approved treatments or [...]
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
09/03/2026
Oak Ridge, TN, March 09, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will participate in the [...]
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
09/03/2026
RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic [...]
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026
09/03/2026
ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth [...]

Pages